KA U IP

Mr. KA U IP

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DLDongliang Leng
Dongliang Leng
ZYZiyi Yang
Ziyi Yang
HSHeng Sun
Heng Sun
CSChengcheng Song
Chengcheng Song
CHChen Huang
Chen Huang
Qi zhaoQi zhao
Qi zhao
Purpose: Sarcoma is the second most common solid tumor type in children and adolescents. The high level of tumor heterogeneity as well as aggressive behavior of sarcomas brings serious difficulties to developing effective therapeutic strategies for clinical application. Therefore, it is of great importance to identify accurate biomarkers for early detection and prognostic prediction of sarcomas. Experimental Design: In this study, we characterized three subtypes of sarcomas based on tumor immune infiltration levels (TIIL), and constructed a prognosis-related competing endogenous RNA (ceRNA) network to investigate molecular regulations in the sarcoma tumor microenvironment (TME). We further built a subnetwork consisting of mRNAs and lncRNAs that are targets of key miRNAs and strongly correlated with each other in the ceRNA network. After validation using public data and experiments in vivo and in vitro, we deeply dug the biological role of the miRNAs and lncRNAs in a subnetwork and their impact on TME. Results: Altogether, 5 miRNAs (hsa-mir-125b-2, hsa-mir-135a-1, hsa-mir92a-2, hsa-mir-181a-2, and hsa-mir-214), 3 lncRNAs (LINC00641, LINC01146, and LINC00892), and 10 mRNAs (AGO2, CXCL10, CD86, CASP1, IKZF1, CD27, CD247, CD69, CCR2, and CSF2RB) in the subnetwork were identified as vital regulators to shape the TME. On the basis of the systematic network, we identified that trichostatin A, a pan-HDAC inhibitor, could potentially regulate the TME of sarcoma, thereby inhibiting the tumor growth. Conclusions: Our study identifies a ceRNA network as a promising biomarker for sarcoma. This system provides a more comprehensive understanding and a novel perspective of how ceRNAs are involved in shaping sarcoma TME.

26 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
XGXinyu Guo
Xinyu Guo
HSHeng Sun
Heng Sun
FYFeng Yu
Feng Yu
YFYangyang Feng
Yangyang Feng
SGSen Guo
Sen Guo
CDChu-xia Deng
Chu-xia Deng
Background/Objectives: Developing effective therapies for patients with triple-negative breast cancer (TNBC) remains an urgent clinical priority. Compared with other subtypes, the basal B type of TNBC exhibits a less differentiated and mesenchymal-like phenotype that models highly invasive and metastatic breast malignancies. To target metastatic TNBC, our current study sought to identify effective therapeutic drugs and the underlying mechanisms. Methods: A systematic screening of 140 FDA-approved drugs was conducted for repurposing using live-cell imaging-based wound-healing assays. Candidate efficacy was validated by in vitro transwell invasion assays, in vivo allograft/xenograft models, and ex vivo three-dimensional air–liquid interface (ALI) and patient-derived organoid (PDO) cultures. Results: Dasatinib emerged as a promising anti-cancer agent in aggressive TNBC, particularly in the basal B type, with high ETS proto-oncogene 1 (ETS1) expression. Mechanistically, dasatinib disrupts the actin cytoskeleton, impairing cell motility and migration while concurrently suppressing the expression of ETS1 and matrix metalloproteinase-3 (MMP3) to remodel the extracellular matrix (ECM) and inhibit invasion. Moreover, the combination of dasatinib with an anti-programmed cell death protein-1 (PD-1) antibody represents a potential therapeutic strategy. Conclusions: These findings highlight dasatinib as a potential therapeutic option for metastatic TNBC and suggest that selecting patients with high ETS1 expression may optimize treatment response.

16 September 2024
Verified
Other
Open access
DLDongliang Leng
Dongliang Leng
ZYZiyi Yang
Ziyi Yang
HSHeng Sun
Heng Sun
CSChengcheng Song
Chengcheng Song
CHChen Huang
Chen Huang
Qi zhaoQi zhao
Qi zhao
Supplementary Table S15. Pearson Correlation Coefficient between target lncRNA and target mRNA of key miRNAs.

16 September 2024
Verified
Other
Open access
DLDongliang Leng
Dongliang Leng
ZYZiyi Yang
Ziyi Yang
HSHeng Sun
Heng Sun
CSChengcheng Song
Chengcheng Song
CHChen Huang
Chen Huang
Qi zhaoQi zhao
Qi zhao
Supplementary Table S3. DE genes in C2 (High) compared with C1 (Low) subtype.

16 September 2024
Verified
Other
Open access
DLDongliang Leng
Dongliang Leng
ZYZiyi Yang
Ziyi Yang
HSHeng Sun
Heng Sun
CSChengcheng Song
Chengcheng Song
CHChen Huang
Chen Huang
Qi zhaoQi zhao
Qi zhao
Supplementary Table S12. MREs between mRNAs and miRNAs in the survival-related ceRNA network.

16 September 2024
Verified
Other
Open access
PDF file
DLDongliang Leng
Dongliang Leng
ZYZiyi Yang
Ziyi Yang
HSHeng Sun
Heng Sun
CSChengcheng Song
Chengcheng Song
CHChen Huang
Chen Huang
Qi zhaoQi zhao
Qi zhao
Supplementary Figure S2. Validation of subtypes of SARC using Consensus clustering analysis.